

REMARKS

Upon entry of the present amendments, claims 1-40 and 42-75 will be pending in this application, claim 41 being cancelled, without prejudice, and new claim 75 being added by amendment herein. Claims 21, 22, 23, 42 and 45 are amended to replace the terms “*Croton* spp.” and “*Calophyllum* spp.” with the terms respectively, “*Croton species*” and “*Calophyllum species*”. Such amendments are merely to correct grammatical usage and are in no way either related to patentability or to limit the subject matter of the claims. Claim 22 is also amended and claim 29 is amended to delete the term “directly compressible”. These amendments broaden claims 22 and 29 and the claims, as amended, are fully supported by the specification and claims as originally filed. See, e.g., the specification at page 12, lines 2-15; at page 17, lines 4-25; at page 20, lines 15-25, etc. New claim 75, dependant upon claim 22 is added to recite that the isolated proanthocyanidin polymer composition is “directly compressible”. Support is found in the specification, e.g., at page 12, lines 15-18; at page 17, lines 18 through page 20, line 9, etc. and original claim 22. Claim 28, as amended, more clearly recites that the capsule is enteric coated. This simply corrects the claims and is not a narrowing amendment as original claim 22, upon which claim 28 depends, recites an “enteric coating”. Claim 32, as amended, recites more clearly the term “irritable” bowel syndrome rather than “inflammatory” bowel syndrome. This amendment is merely to be consistent with the term for secretory diarrhea associated with irritable bowel syndrome as would be understood by those skilled in the art.

Thus, all the claims are fully supported by the specification as filed and no new matter is added.

Restriction has been required to one of the following 8 groups:

Group I: Claims 1-20 drawn to a proanthocyanidin polymer composition, classified in Class 424, subclass 78.08, for example.

- Group II: Claims 21-47 drawn to a process of treating secretory diarrhea with a proanthocyanidin polymer composition and optionally with another suitable anti-diarrheic, classified in Class 514, subclass 867, for example.
- Group IV: Claims 48-69 drawn to a process of preventing secretory diarrhea with a proanthocyanidin polymer composition, classified in Class 424, subclass 78.01, for example.
- Group V: Claim 70 to a process of isolating a directly compressible proanthocyanidin polymer from *Croton* classified in Class 424, subclass 195.1, for example.
- Group VI: Claims 71-72 thiazolidinedione derivatives to a directly compressible proanthocyanidin polymer composition, classified in Class 424, subclass 400, for example.
- Group VII: Claim 73 drawn to a process of treating secretory diarrhea with a directly compressible proanthocyanidin polymer composition, classified in Class 514, subclass 867, for example.
- Group VIII: Claim 74 drawn to a process of preventing secretory diarrhea with a directly compressible proanthocyanidin polymer composition, classified in Class 424, subclass 78.01, for example.

In response, Applicants elect, with traverse, to prosecute the subject matter of Group II, directed to methods for treating secretory diarrhea. Claims 21-40 and 42-47 and 75 are in the elected group. All rights are reserved to prosecute non-elected subject matter in a continuation or divisional application.


Submitted herewith is an Information Disclosure Statement with PTO form 1449 listing references A01-A04; B01; and C01-C43. It is requested that all the references be made of record in this file.

CONCLUSION

In light of the above, it is submitted the claims are in form for allowance.

Respectfully submitted,

Date: October 22, 2003


Geraldine F. Baldwin

31,232
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures